EUCTR2009-014490-41-GB进行中（未招募）不适用
A multicenter, double-blind, placebo-controlled Phase 3 study assessingthe safety and efficacy of selexipag on morbidity and mortality in patientswith pulmonary arterial hypertension - GRIPHO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent prior to initiation of any study-mandated procedure.
- •- Male and female patients aged from 18 years to 75 years inclusive with symptomatic PAH.
- •- Documented hemodynamic diagnosis of PAH.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) within 1 month before Baseline Visit, or are
- •scheduled to receive any of these compounds during the trial.
- •- Patients with moderate or severe obstructive lung disease.
- •- Patients with moderate or severe restrictive lung disease.
- •- Patients with moderate or severe hepatic impairment (Child-Pugh B and C).
- •- Patients with documented left ventricular dysfunction.
- •- Patients with severe renal insufficiency.
- •- Patients with BMI <18.5 Kg/m2.
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate if selexipag is safe and efficacious for the treatment ofpulmonary arterial hypertension.The intended indication is Pulmonary Arterial HypertensionMedDRA version: 16.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014490-41-NLActelion Pharmaceuticals Ltd1,150
进行中（未招募）
1 期
Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertension.The intended indication is Pulmonary Arterial HypertensionMedDRA version: 15.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014490-41-BEActelion Pharmaceuticals Ltd1,150
进行中（未招募）
不适用
Study to evaluate if selexipag is safe and efficacious for the treatment ofpulmonary arterial hypertension.The intended indication is Pulmonary Arterial HypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014490-41-CZActelion Pharmaceuticals Ltd1,150
招募中
3 期
Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertensioCTRI/2011/06/001842ACTELION Pharmaceuticals Ltd670
进行中（未招募）
1 期
Phase I/II study of a new immunotherapeutic anticancer treatment administered in combination with standard therapy before surgery in patients with primary invasive breast cancer.eoadjuvant treatment of WT1-positive Stage II or III breast cancer. Patients will receive the WT1-A10 + AS15 ASCI in combination with standard neodjuvant therapy. Patients will be recruited in different cohorts according to the standard neoadjuvant treatment they will receive (aromatase inhibitor, chemotherapy or chemotherapy combined with trastuzumab).MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019909-42-GBGlaxoSmithKline Biologicals60